AMARILLO BIOSCIENCES INC
SC 13G, 1996-09-06
PHARMACEUTICAL PREPARATIONS
Previous: DARUMA FUNDS INC, 497, 1996-09-06
Next: AMARILLO BIOSCIENCES INC, SC 13G, 1996-09-06




- ------------------------------

        OMB APPROVAL
- ------------------------------

OMB Number:  3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response.....14.90
- ------------------------------



                                  SCHEDULE 13G

             INFORMATION STATEMENT PURSUANT TO RULES 13d-1 and 13d-2

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                                (AMENDMENT NO. )*




                           AMARILLO BIOSCIENCES, INC.
                           --------------------------
                                (Name of Issuer)


                     Common Stock, par value $.01 per share
                     --------------------------------------
                         (Title of Class of Securities)


                                    02301P106
                                    ---------
                                 (CUSIP Number)





Check the following box if a fee is being paid with this  statement  [X]. (A fee
is not required only if the filing person:  (1) has a previous statement on file
reporting  beneficial  ownership  of more  than  five  percent  of the  class of
securities  described  in Item 1;  and (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial  ownership of five percent or less of such class.)
(See Rule 13d-7.)

* The remainder of this cover page should be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 or  otherwise  subject to the  liabilities  of that  section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).



                                page 1 of 5 pages

<PAGE>



                                  SCHEDULE 13G

CUSIP No. 02301P106                                       Page 2 of 5 Pages
          --------- 

1    NAME OF  REPORTING  PERSONS  S.S.  OR  I.R.S.  IDENTIFICATION  NO. OF ABOVE
     PERSONS

     Joseph M. Cummins


2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)



3    SEC USE ONLY



4    CITIZENSHIP OR PLACE OR ORGANIZATION

     United States of America


5    NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH  REPORTING  PERSON  WITH SOLE
     VOTING POWER

     696,444


6    NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING  PERSON WITH SHARED
     VOTING POWER

     360


7    NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH  REPORTING  PERSON  WITH SOLE
     DISPOSITIVE POWER

     696,444


8    NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING  PERSON WITH SHARED
     DISPOSITIVE POWER

     360


9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     696,804


10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*



11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     13.6% 


12   TYPE OF REPORTING PERSON*

     IN

                      *SEE INSTRUCTION BEFORE FILLING OUT!




                                page 2 of 5 pages

<PAGE>


ITEM 1(A).        NAME OF ISSUER:

Amarillo Biosciences, Inc.


ITEM 1(B).        ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

800 West 9th Avenue
Amarillo, Texas  79101


ITEM 2(A).        NAME OF PERSON FILING:

This statement is being filed by Joseph M. Cummins,  an individual  ("Cummins").
Cummins  is making  the  filing  because  he owns of record the shares of Common
Stock,  par value $.01 per share,  of  Amarillo  Biosciences,  Inc.  reported as
beneficially owned by him.


ITEM 2(B).        ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE:

The principal business office of Cummins is 800 West 9th Avenue, Amarillo, Texas
79101.


ITEM 2(C).        CITIZENSHIP:

Cummins is a citizen of the United States of America.


ITEM 2(D).        TITLE OF CLASS OF SECURITIES:

Common Stock, par value $.01 per share, of Amarillo  Biosciences,  Inc. ("Common
Stock")


ITEM 2(E).        CUSIP NUMBER:

02301P106


ITEM 3.           IF THIS STATEMENT IS FILED  PURSUANT TO RULE 13D-1(B),  OR
                  13D-2(B), CHECK WHETHER THE PERSON IS:

Not applicable


ITEM 4.  OWNERSHIP:

         (a)  Amount Beneficially Owned:

                  696,804 shares

         (b)      Percent of Class:

                  13.6%

                                page 3 of 5 pages


<PAGE>

         (c)      Number of shares as to which such person has:

           (i)    sole power to vote or direct the vote:                696,444
          (ii)    shared power to vote or direct the vote:              360
         (iii)    sole power to dispose or direct the disposition of:   696,444
          (iv)    shared power to dispose or direct the disposition of: 360


ITEM 5.  OWNERSHIP OF FIVE PERCENT OR LESS OR A CLASS.

If this  statement is being filed to report the fact that as of the date hereof,
the  reporting  person has ceased to be the  beneficial  owner of more than five
percent of the class of securities, check the following. [ ]


ITEM 6.  OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not applicable


ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
         SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not applicable


ITEM 8.  IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable


ITEM 9.  NOTICE OF DISSOLUTION OF GROUP.

Not applicable.


ITEM 10. CERTIFICATION.

Not applicable.

                                page 4 of 5 pages


<PAGE>


                                    SIGNATURE




                  After  reasonable  inquiry and to the best of my knowledge and
belief,  I certify  that the  information  set forth in this  statement is true,
complete and correct.




Dated:  September 5, 1996



                                           /s/ Joseph M. Cummins
                                           ---------------------
                                           Joseph M. Cummins



                                page 5 of 5 pages




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission